PetVivo's Spryng Joint Treatment Gains Health Canada Nod for Pets

MINNEAPOLIS, MN – January 21, 2026 – PetVivo Holdings, Inc. has secured a key regulatory milestone in its global expansion strategy, announcing that Health Canada has formally acknowledged its Spryng® with OsteoCushion® Technology as a veterinary medical device. The decision opens the door for the innovative joint-health treatment to enter the burgeoning Canadian animal healthcare market, with the company targeting commercial availability in the second quarter of 2026.

Spryng is a veterinarian-administered, intra-articular injectable designed to support joint health and manage lameness in companion animals and equine athletes. The product’s acknowledgement by a major international regulatory body like Health Canada is a significant validation for the emerging biomedical device company.

“Receiving acknowledgment from Health Canada that Spryng meets the criteria for a veterinary medical device is an important endorsement of our scientific and regulatory strategy,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “This acknowledgment reflects our continued commitment to expanding access to innovative, safe, and effective solutions that improve the health and mobility of companion animals and athletic equines.”

A New Frontier for Animal Joint Health in Canada

The timing of Spryng’s potential entry aligns with powerful trends in the Canadian market. Pet ownership is on the rise, with a 2022 survey indicating that 60% of Canadian households own at least one dog or cat. This translates to a growing population of 7.9 million dogs and 8.5 million cats, many of whom are living longer and experiencing age-related health issues like osteoarthritis.

Canada’s animal healthcare market reflects this trend, with estimates projecting its value to grow from approximately USD 2.98 billion in 2025 to USD 4.23 billion by 2030. A significant portion of this spending is directed toward dogs and cats, which command nearly half of the market share. For horses, joint afflictions are a primary concern, with an estimated 60% of lameness cases linked to arthritis. The introduction of a new medical device aimed at managing these conditions is poised to address a clear and growing need among Canadian veterinarians and pet owners who are increasingly investing in advanced care and wellness products for their animals.

PetVivo's Strategic Play in a Growing Global Market

For PetVivo, the Canadian acknowledgement is a critical step in a broader commercial strategy focused on leveraging human medical technologies for the veterinary space. This approach allows for a more capital-efficient and accelerated path to market compared to heavily regulated pharmaceuticals. Spryng, along with the company's platelet-rich plasma product PrecisePRP®, is at the forefront of this effort.

Financially, the company is in a growth phase. PetVivo reported a 6% increase in revenue to $969,000 for fiscal year 2024, largely fueled by a 15% rise in sales through its expanding distributor network. The company has guided for significant revenue growth of 50% to 100% for fiscal year 2025, with strong gross margins that recently approached 90%. This performance is supported by a growing footprint in the United States, where Spryng is now available in over 800 veterinary clinics across all 50 states, bolstered by a key distribution partnership with Covetrus North America.

However, this growth has required substantial investment, and the company is not yet profitable, reporting a net loss of $2.2 million in its second fiscal quarter of 2025. The expansion into Canada represents a calculated move to scale its operations and capture new revenue streams that are essential for its long-term path to profitability.

The Science and the Competition

Spryng with OsteoCushion® Technology is designed to function as a bio-integrative solution. Unlike treatments that may only manage symptoms like pain and inflammation, PetVivo's device is composed of biocompatible particles that are injected into the joint. The company states these particles function as a scaffold, providing cushioning and support to damaged cartilage, thereby addressing underlying mechanical issues associated with joint afflictions.

Upon entering the Canadian market, Spryng will face an established field of competitors. The joint health landscape currently includes a wide array of oral supplements containing ingredients like glucosamine, chondroitin, and hyaluronic acid from brands such as UBAVET. For more advanced cases, particularly in horses, veterinarians have access to injectable treatments like Legend (sodium hyaluronate) and Adequan (polysulfated glycosaminoglycan), which are widely used to manage joint dysfunction and arthritis. PetVivo aims to differentiate Spryng by positioning it as a device that offers a novel mechanism of action, potentially providing a durable, long-term solution rather than just temporary relief.

The Road to Commercialization

Despite the positive regulatory news, Canadian veterinarians and animal owners will need to wait before Spryng is available. PetVivo has indicated that the projected launch in the second quarter of 2026 is contingent upon clearing several operational hurdles. Chief among these are the establishment of a Canadian distribution infrastructure, the development of country-specific packaging and labeling that complies with Health Canada regulations, and securing necessary site licenses for storage and handling.

Entering the Canadian medical device market is a complex logistical undertaking that often requires specialized partners. Companies must adhere to strict Good Manufacturing Practices (GMP) and may need to secure temperature-controlled supply chains to ensure product integrity from a warehouse to a veterinary clinic. This preparatory phase is critical for a successful launch and is the primary focus for PetVivo over the coming year.

As the company works to finalize these arrangements, the Canadian veterinary community will be watching. The eventual arrival of Spryng could offer a significant new tool for managing one of the most common and debilitating conditions affecting the nation's beloved companion animals and high-performance equines.